-
ICD-10-CM Codes
›
-
C00-D49
›
-
C81-C96
›
-
C92-
›
-
2023 ICD-10-CM Diagnosis Code C92.02
2023 ICD-10-CM Diagnosis Code C92.02
Acute myeloblastic leukemia, in relapse
2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
- C92.02 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2023 edition of ICD-10-CM C92.02 became effective on October 1, 2022.
- This is the American ICD-10-CM version of C92.02 - other international versions of ICD-10 C92.02 may differ.
The following code(s) above
C92.02 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to
C92.02:
- C00-D49
2023 ICD-10-CM Range C00-D49
NeoplasmsNote- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
- C81-C96
2023 ICD-10-CM Range C81-C96
Malignant neoplasms of lymphoid, hematopoietic and related tissueType 2 Excludes- Kaposi's sarcoma of lymph nodes (C46.3)
- secondary and unspecified neoplasm of lymph nodes (C77.-)
- secondary neoplasm of bone marrow (C79.52)
- secondary neoplasm of spleen (C78.89)
- C92
ICD-10-CM Diagnosis Code C92
Myeloid leukemia
2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
Includes- granulocytic leukemia
- myelogenous leukemia
Type 1 Excludes- personal history of leukemia (Z85.6)
- C92.0
ICD-10-CM Diagnosis Code C92.0
Acute myeloblastic leukemia
2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
Applicable To- Acute myeloblastic leukemia, minimal differentiation
- Acute myeloblastic leukemia (with maturation)
- Acute myeloblastic leukemia 1/ETO
- Acute myeloblastic leukemia M0
- Acute myeloblastic leukemia M1
- Acute myeloblastic leukemia M2
- Acute myeloblastic leukemia with t(8;21)
- Acute myeloblastic leukemia (without a FAB classification) NOS
- Refractory anemia with excess blasts in transformation [RAEB T]
Type 1 Excludes- acute exacerbation of chronic myeloid leukemia (C92.10)
- refractory anemia with excess of blasts not in transformation (D46.2-)
- Acute myelocytic leukemia in relapse
- Acute myelocytic leukemia w maturation, in relapse
- Acute myelocytic leukemia wo maturation, in relapse
- Acute myelocytic leukemia, fab m0, in relapse
- Acute myeloid leukemia with maturation, fab m2 in relapse
- Acute myeloid leukemia without maturation, fab m1 in relapse
- Refractory anemia w excess blasts in transformation, i
- Refractory anemia with excess blasts in transformation in relapse
ICD-10-CM C92.02 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):
- 820 Lymphoma and leukemia with major o.r. Procedures with mcc
- 821 Lymphoma and leukemia with major o.r. Procedures with cc
- 822 Lymphoma and leukemia with major o.r. Procedures without cc/mcc
- 834 Acute leukemia without major o.r. Procedures with mcc
- 835 Acute leukemia without major o.r. Procedures with cc
- 836 Acute leukemia without major o.r. Procedures without cc/mcc
- 837 Chemotherapy with acute leukemia as secondary diagnosis or with high dose chemotherapy agent with mcc
- 838 Chemotherapy with acute leukemia as secondary diagnosis with cc or high dose chemotherapy agent
- 839 Chemotherapy with acute leukemia as secondary diagnosis without cc/mcc
Convert C92.02 to ICD-9-CM
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
ICD-10-CM Codes Adjacent To C92.02
C91.9 Lymphoid leukemia, unspecified
C91.90 …… not having achieved remission
C92.0 Acute myeloblastic leukemia
C92.00 …… not having achieved remission
C92.02
…… in relapse
C92.1 Chronic myeloid leukemia, BCR/ABL-positive
C92.10 …… not having achieved remission
C92.2 Atypical chronic myeloid leukemia, BCR/ABL-negative
C92.20 …… not having achieved remission
C92.30 …… not having achieved remission
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.
